View details of this raise on Seedstage

Hayward, CA

Developing engineered human tissues to address organ shortages and reduce animal testing.

• Human Tissue Models: Frontier Bio creates lab-grown human tissue models as alternatives to animal studies, enhancing preclinical testing accuracy.
• Regenerative Vascular Grafts: The company is developing vascular grafts that use patient stem cells to transform into natural blood vessels, addressing synthetic graft limitations.
• Revenue Generation: Frontier Bio generates revenue through sales of tissue models and R&D services to commercial partners, academic institutions, and government.
• Market Opportunity: The company operates in a multi-billion-dollar market for human tissue models and vascular grafts, with significant growth potential.
• Strategic Collaborations: Frontier Bio collaborates with top-tier institutions to advance medical science and develop next-generation therapies.

Frontier Bio is advancing the field of human tissue engineering with the aim of addressing critical healthcare challenges. The company is focused on developing lab-grown human tissue models that serve as high-fidelity alternatives to animal studies, providing a human-relevant platform for evaluating safety and biological activity. These models are designed to support the evaluation of a range of therapeutic approaches, from pharmaceutical drugs to novel cell therapies. Frontier Bio collaborates with partners to use these models to support the development of next-generation therapies.

In addition to tissue models, Frontier Bio is developing a regenerative vascular graft designed to use the patients own stem cells to address the high failure rate of purely synthetic grafts. By combining the patients own cells with a bioresorbable scaffold, the graft is engineered to transform into a natural blood vessel over time after implantation. This approach aims to provide a long-term solution that overcomes the limitations of synthetic materials. Frontier Bio’s work in tissue engineering lays the groundwork for future regenerative medicine applications, including transplantable organs, positioning the company to address significant unmet needs in the healthcare sector.

Company Info

Frontier Bio develops engineered human tissues to address organ shortages and reduce reliance on animal testing.

Frontier Bio focuses on engineering human tissues to address critical healthcare challenges, such as the organ shortage and the limitations of animal testing. The company develops lab-grown human tissue models that serve as high-fidelity alternatives to animal studies, providing a human-relevant platform for evaluating the safety and biological activity of new therapies. These models are used by pharmaceutical companies and research institutions to improve the accuracy of preclinical testing and support the development of next-generation therapies.

In addition to tissue models, Frontier Bio is advancing its tissue engineering expertise toward creating implantable products, such as living, tissue-engineered vascular grafts. These grafts are designed to transform into natural blood vessels within the patient’s body, offering a potential solution to the high failure rates of synthetic grafts. By focusing on critical procedures like dialysis access and coronary artery bypass, Frontier Bio aims to provide long-term solutions that integrate naturally with the body, reducing the need for additional surgeries and improving patient outcomes.